AAAAAA

   
Results: 1-18 |
Results: 18
Lipid-based formulations for oral administration: Opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs (Reprinted from Drug Targeting Technology: Physical - Chemical - Biological Methods - Drugs and the Pharmaceutical Sciences, vol 115, pg 85-130, 2001)
Authors: Porter, CJH Charman, WN
Citation: Cjh. Porter et Wn. Charman, Lipid-based formulations for oral administration: Opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs (Reprinted from Drug Targeting Technology: Physical - Chemical - Biological Methods - Drugs and the Pharmaceutical Sciences, vol 115, pg 85-130, 2001), J RECEPT SI, 21(2-3), 2001, pp. 215-257
Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situdensitometric analysis
Authors: Sek, L Porter, CJH Charman, WN
Citation: L. Sek et al., Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situdensitometric analysis, J PHARM B, 25(3-4), 2001, pp. 651-661
Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model
Authors: Charman, SA McLennan, DN Edwards, GA Porter, CJH
Citation: Sa. Charman et al., Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model, PHARM RES, 18(11), 2001, pp. 1620-1626
Preface - Transport and absorption of drugs via the lymphatic system
Authors: Porter, CJH Charman, WN
Citation: Cjh. Porter et Wn. Charman, Preface - Transport and absorption of drugs via the lymphatic system, ADV DRUG DE, 50(1-2), 2001, pp. 1-2
Animal models for the study of intestinal lymphatic drug transport
Authors: Edwards, GA Porter, CJH Caliph, SM Khoo, SM Charman, WN
Citation: Ga. Edwards et al., Animal models for the study of intestinal lymphatic drug transport, ADV DRUG DE, 50(1-2), 2001, pp. 45-60
Intestinal lymphatic drug transport: an update
Authors: Porter, CJH Charman, WN
Citation: Cjh. Porter et Wn. Charman, Intestinal lymphatic drug transport: an update, ADV DRUG DE, 50(1-2), 2001, pp. 61-80
Lymphatic transport of proteins after s.c. injection: implications of animal model selection
Authors: Porter, CJH Edwards, GA Charman, SA
Citation: Cjh. Porter et al., Lymphatic transport of proteins after s.c. injection: implications of animal model selection, ADV DRUG DE, 50(1-2), 2001, pp. 157-171
In vitro assessment of oral lipid based formulations
Authors: Porter, CJH Charman, WN
Citation: Cjh. Porter et Wn. Charman, In vitro assessment of oral lipid based formulations, ADV DRUG DE, 50, 2001, pp. S127-S147
A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine
Authors: Khoo, SM Edwards, GA Porter, CJH Charman, WN
Citation: Sm. Khoo et al., A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine, J PHARM SCI, 90(10), 2001, pp. 1599-1607
Lipid-based formulations for oral administration - Opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs
Authors: Porter, CJH Charman, WN
Citation: Cjh. Porter et Wn. Charman, Lipid-based formulations for oral administration - Opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs, DRUG PHARM, 115, 2001, pp. 85-130
The formulation of Halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: Physical stability and absolute bioavailability assessment
Authors: Khoo, SM Porter, CJH Charman, WN
Citation: Sm. Khoo et al., The formulation of Halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: Physical stability and absolute bioavailability assessment, INT J PHARM, 205(1-2), 2000, pp. 65-78
Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion
Authors: Lyons, KC Charman, WN Miller, R Porter, CJH
Citation: Kc. Lyons et al., Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion, INT J PHARM, 199(1), 2000, pp. 17-28
Effect of short-, medium-, and long-chain fatty acid-based vehicles on theabsolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats
Authors: Caliph, SM Charman, WN Porter, CJH
Citation: Sm. Caliph et al., Effect of short-, medium-, and long-chain fatty acid-based vehicles on theabsolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats, J PHARM SCI, 89(8), 2000, pp. 1073-1084
Lymphatic transport of proteins after subcutaneous administration
Authors: Porter, CJH Charman, SA
Citation: Cjh. Porter et Sa. Charman, Lymphatic transport of proteins after subcutaneous administration, J PHARM SCI, 89(3), 2000, pp. 297-310
Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection
Authors: Charman, SA Segrave, AM Edwards, GA Porter, CJH
Citation: Sa. Charman et al., Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection, J PHARM SCI, 89(2), 2000, pp. 168-177
Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of coreapolar lipoprotein lipid
Authors: McIntosh, MP Porter, CJH Wasan, KM Ramaswamy, M Charman, WN
Citation: Mp. Mcintosh et al., Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of coreapolar lipoprotein lipid, J PHARM SCI, 88(3), 1999, pp. 378-384
Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: In vitro studies in normolipidemic and dyslipidemic humanplasmas
Authors: Wasan, KM Ramaswamy, M McIntosh, MP Porter, CJH Charman, WN
Citation: Km. Wasan et al., Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: In vitro studies in normolipidemic and dyslipidemic humanplasmas, J PHARM SCI, 88(2), 1999, pp. 185-190
Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole
Authors: Khoo, SM Porter, CJH Edwards, GA Charman, WN
Citation: Sm. Khoo et al., Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole, J PHARM SCI, 87(12), 1998, pp. 1538-1541
Risultati: 1-18 |